KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
Zacks Investment Research on MSN
Will Keytruda continue to aid Merck's top line in Q4 earnings?
A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...
US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...
As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...
Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer ...
ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...
The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...
The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...
Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback